Global Chronic Liver Diseases Therapeutics Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to more than 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in more than 14.5 million infected individuals worldwide as of July 2020. COVID-19 can affect the global economy in three main ways; by directly affecting production and demand, by negatively impacting the supply chain and market disruption, and by its financial impact on firms and financial markets.
Get PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/4047
Due to the lockdown, many countries such as Italy, Spain, U.K., the U.S., Australia, India, and others are facing problems of lockdown in countries. Moreover, several countries are facing a severe economic crisis, and market recovery is likely to be slow. The pandemic has negative impact on pharmaceutical industry in terms of supply and demand of different drugs. Similarly, it is also projected to impact growth of the global chronic liver disease therapeutics market.
Furthermore, the growing prevalence of chronic liver disease is projected to augment demand for liver diseases therapeutics drugs in the near future. For instance, according to data published by the Centers for Disease Control and Prevention, between 2000 and 2015, the rate of deaths resulting from chronic liver disease and cirrhosis in the U.S. increased by 31%.
Moreover, increasing number of clinical trials of new therapies are projected to support growth of the market. For instance, in March 2018, the U.S. FDA granted Orphan Drug Designation for Protagonist Therapeutics, Inc.’s PTG-300; a subcutaneous injectable in clinical development stage for the potential treatment of beta-thalassemia and liver fibrosis.
Key Takeaways of Global Chronic Liver Diseases Therapeutics Market:
- The global chronic liver diseases therapeutics market is expected to exhibit a CAGR of 9.7% during the forecast period (2020-2027) owing to the growing prevalence of liver cancer.
- Among therapy type, antiviral drugs segment is expected to hold major revenue share in 2027 owing to drug launches. For instance, in March 2020, the U.S. Food and Drug Administration (FDA) approved a combination of checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) for advanced hepatocellular carcinoma, a liver cancer.
- Major players engaged in the global chronic liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/4047
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Chronic Liver Diseases Therapeutics Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Chronic Liver Diseases Therapeutics Industry Impact
Chapter 2 Global Chronic Liver Diseases Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Chronic Liver Diseases Therapeutics (Volume and Value) by Type
2.3 Global Chronic Liver Diseases Therapeutics (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Chronic Liver Diseases Therapeutics Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Chronic Liver Diseases Therapeutics Market Analysis
Chapter 6 East Asia Chronic Liver Diseases Therapeutics Market Analysis
Chapter 7 Europe Chronic Liver Diseases Therapeutics Market Analysis
Chapter 8 South Asia Chronic Liver Diseases Therapeutics Market Analysis
Chapter 9 Southeast Asia Chronic Liver Diseases Therapeutics Market Analysis
Chapter 10 Middle East Chronic Liver Diseases Therapeutics Market Analysis
Chapter 11 Africa Chronic Liver Diseases Therapeutics Market Analysis
Chapter 12 Oceania Chronic Liver Diseases Therapeutics Market Analysis
Chapter 13 South America Chronic Liver Diseases Therapeutics Market Analysis
Chapter 14 Company Profiles and Key Figures in Chronic Liver Diseases Therapeutics Business
Chapter 15 Global Chronic Liver Diseases Therapeutics Market Forecast (2022-2028)
Chapter 16 Conclusions
Buy This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/4047
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027